Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript

🇺🇸 Seeking Alpha (US) —
Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript

AI Summary

Sagimet Biosciences discussed 52-week Phase 3 data and U.S. Phase 3 plans for denifanstat, an investigational treatment for moderate to severe acne. The supplied headline does not provide study results or further details.

Markets Health Sagimet Biosciences denifanstat acne Phase 3 clinical data drug development

Read original source →